scholarly journals Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

2020 ◽  
Vol 223 (1) ◽  
pp. 23-27 ◽  
Author(s):  
Ji Hoon Baang ◽  
Christopher Smith ◽  
Carmen Mirabelli ◽  
Andrew L Valesano ◽  
David M Manthei ◽  
...  
Keyword(s):  
Sequence Analysis ◽  
Severe Acute Respiratory Syndrome ◽  
B Cell ◽  
Humoral Immunity ◽  
Immunocompromised Patient ◽  
Immunocompromised Hosts

Abstract We describe a case of chronic coronavirus disease 2019 (COVID-19) in a patient with lymphoma and associated B-cell immunodeficiency. Viral cultures and sequence analysis demonstrate ongoing replication of infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for at least 119 days. The patient had 3 admissions related to COVID-19 over a 4-month period and was treated twice with remdesivir and convalescent plasma with resolution of symptoms. The patient’s lack of seroconversion and prolonged course illustrate the importance of humoral immunity in resolving SARS-CoV-2 infection. This case highlights challenges in managing immunocompromised hosts, who may act as persistent shedders and sources of transmission.

scholarly journals Prolonged SARS-CoV-2 replication in an immunocompromised patient

2020 ◽  
Author(s):  
Ji Hoong Baang ◽  
Christopher Smith ◽  
Carmen Mirabelli ◽  
Andrew L. Valesano ◽  
David M. Manthei ◽  
...  
Keyword(s):  
Sequence Analysis ◽  
B Cell ◽  
Humoral Immunity ◽  
Immunocompromised Patient ◽  
Immunocompromised Hosts

We describe a case of chronic COVID-19 in a patient with lymphoma and associated B-cell immunodeficiency. Viral cultures and sequence analysis demonstrate ongoing replication of infectious SARS-CoV-2 virus for at least 119 days. The patient had three admissions related to COVID-19 over a four-month period and was treated twice with remdesivir and convalescent plasma with resolution of symptoms. The lack of seroconversion and prolonged course illustrate the importance of humoral immunity in resolving SARS-CoV-2 infection. This case highlights challenges in managing immunocompromised hosts, who may act as persistent shedders and sources of transmission.

Author response for "Human pregnancy levels of estrogen and progesterone contribute to humoral immunity by activating T FH /B cell axis"

2020 ◽  
Author(s):  
Clarice Monteiro ◽  
Taissa Kasahara ◽  
Priscila M. Sacramento ◽  
Aleida Dias ◽  
Simone Leite ◽  
...  
Keyword(s):  
B Cell ◽  
Humoral Immunity ◽  
Author Response ◽  
Cell Axis ◽  
Human Pregnancy

IMMU-29. B-CELL-BASED VACCINE PRODUCES GLIOBLASTOMA-REACTIVE ANTIBODIES THAT CONTRIBUTE TO TUMOR CLEARANCE

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi98-vi98
Author(s):  
Brandyn Castro ◽  
Mark Dapash ◽  
David Hou ◽  
Aida Rashidi ◽  
Deepak Kanojia ◽  
...  
Keyword(s):  
B Cells ◽  
B Cell ◽  
Humoral Immunity ◽  
Ex Vivo ◽  
Murine Models ◽  
Effector Functions ◽  
Tumor Bearing ◽  
Tumor Clearance ◽  
Cellular And Humoral Immunity

Abstract Glioblastomas (GBM) are characterized by a strong immunosuppressive environment, contributing to their poor prognosis and limited therapeutic response to immunotherapies. B-cells represent a unique opportunity to promote immunotherapy due to their potential to kill tumors by both cellular and humoral immunity. To generate our B-cell-based vaccine (BVax) platform, we activated 41BBL+ B cells from tumor bearing mice or GBM patient blood with BAFF, CD40, and IFNg. We have previously demonstrated that BVax potentiates radiation therapy, temozolomide and checkpoint blockade in murine models of GBM via enhancement of CD8+ T-cell based immunity. The aim of this current study is to evaluate the humoral effector functions of BVax. We examined the antibody (Ab) repertoire in vivo from serum of tumor-bearing B-cell knockout mice treated with BVax or by ex vivo stimulation of patient-derived BVax. Upon systemic administration, BVax infiltrates the tumor where it differentiates into plasmablasts. Murine BVax- and BNaive-derived serum immunoglobulin generated in vivo showed that the majority of murine BVax-derived Ab were IgG isotype, while BNaive mainly produced IgM isotype. Transfer of IgG from BVax treated mice directly into tumors of recipient animals significantly prolonged their survival, demonstrating anti-tumor cytotoxicity directly through humoral immunity. Patient-derived BVax activated ex vivo showed a plasmablast phenotype and the Ab repertoire supports the previous findings seen in our murine model. Our work suggests BVax-derived IgGs role in antibody-dependent cellular cytotoxicity and improved survival in murine models. This function, in addition to its role in cellular immunity against GBM, renders BVax a potentially effective alternative immunotherapeutic option for GBM patients.

scholarly journals Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity

2012 ◽  
Vol 14 (2) ◽  
pp. R57 ◽  
Author(s):  
YK Onno Teng ◽  
Gillian Wheater ◽  
Vanessa E Hogan ◽  
Philip Stocks ◽  
EW Nivine Levarht ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
B Cell ◽  
Humoral Immunity ◽  
Cell Depletion ◽  
B Cell Depletion ◽  
Refractory Rheumatoid Arthritis
Sign in / Sign up

Export Citation Format

Share Document